Y9J

Treprostinil

Created:	2023-11-28
Last modified:	2024-11-11

Find Related PDB Entry
1 entries where Y9J is found as a standalone ligand

Help Find related ligands:
Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Help

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	62
Chiral Atom Count	5
Bond Count	64
Aromatic Bond Count	6

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	Treprostinil
Synonyms	2-[[(1~{R},2~{R},3~{a}~{S},9~{a}~{S})-2-oxidanyl-1-[(3~{S})-3-oxidanyloctyl]-2,3,3~{a},4,9,9~{a}-hexahydro-1~{H}-cyclopenta[g]naphthalen-5-yl]oxy]ethanoic acid
Systematic Name (OpenEye OEToolkits)	2-[[(1~{R},2~{R},3~{a}~{S},9~{a}~{S})-2-oxidanyl-1-[(3~{S})-3-oxidanyloctyl]-2,3,3~{a},4,9,9~{a}-hexahydro-1~{H}-cyclopenta[g]naphthalen-5-yl]oxy]ethanoic acid
Formula	C₂₃ H₃₄ O₅
Molecular Weight	390.513
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	CACTVS	3.385	CCCCC[CH](O)CC[CH]1[CH](O)C[CH]2Cc3c(C[CH]12)cccc3OCC(O)=O
SMILES	OpenEye OEToolkits	2.0.7	CCCCCC(CCC1C2Cc3cccc(c3CC2CC1O)OCC(=O)O)O
Canonical SMILES	CACTVS	3.385	CCCCC[C@H](O)CC[C@H]1[C@H](O)C[C@@H]2Cc3c(C[C@H]12)cccc3OCC(O)=O
Canonical SMILES	OpenEye OEToolkits	2.0.7	CCCCC[C@@H](CC[C@@H]1[C@H]2Cc3cccc(c3C[C@H]2C[C@H]1O)OCC(=O)O)O
InChI	InChI	1.06	InChI=1S/C23H34O5/c1-2-3-4-7-17(24)9-10-18-19-11-15-6-5-8-22(28-14-23(26)27)20(15)12-16(19)13-21(18)25/h5-6,8,16-19,21,24-25H,2-4,7,9-14H2,1H3,(H,26,27)/t16-,17-,18+,19-,21+/m0/s1
InChIKey	InChI	1.06	PAJMKGZZBBTTOY-ZFORQUDYSA-N

Drug Info: DrugBank

DrugBank ID	DB00374
Name	Treprostinil
Groups	approved investigational
Description	Treprostinil is a stable tricyclic analogue of prostacyclin[A248770] that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease.[L41855,L41860] The first agent approved for the treatment of PAH was [epoprostenol], a synthetic prostacyclin that significantly increases patients' quality of life. However, the use of epoprostenol is limited due to its short half-life (3-5 min) and instability at room temperature.[A248770,A248775] The use of more stable alternatives such as treprostinil provides patients with PAH with more treatment options. Treprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension.[L41860] It is available in the following routes of administration: subcutaneous, intravenous, inhaled and oral. The first generic form of treprostinil became available in 2019.[A248775]
Synonyms	Treprostinil diolamine Tréprostinil Treprostinil sodium Treprostinil Treprostinilum Treprostinilo
Brand Names	Treprostinil Injection Orenitram Tyvaso Tyvaso DPI Trepulmix Treprostinil Remodulin
Indication	The FDA has indicated treprostinil for the treatment of pulmonary arterial hypertension[L41855,L41860,L41865] and pulmonary hypertension associated with interstitial lung disease[L41855] to improve exercise ability. It is also used to treat pulmonary arterial hypertension in patients requiring transition from epoprostenol.[L41860] The Health Canada label specifies that treprostinil is indicated for the long-term treatment of pulmonary arterial hypertension in NYHA Class III and IV patients who did not respond adequately to conventional therapy.[L24244] L24244
Categories	Antihypertensive Agents Autacoids Biological Factors Blood and Blood Forming Organs Cardiovascular Agents Cytochrome P-450 CYP2C8 Substrates Cytochrome P-450 CYP2C9 Substrates Cytochrome P-450 Substrates Eicosanoids Fatty Acids Fatty Acids, Unsaturated Inflammation Mediators Lipids Platelet Aggregation Inhibitors Excl. Heparin Potential QTc-Prolonging Agents Prostacyclin Analogues Prostacycline Vasodilator Prostaglandins Prostaglandins I QTc Prolonging Agents Vasodilating Agents Vasodilation
ATC-Code	B01AC21
CAS number	81846-19-7

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Prostacyclin receptor	MADSCRNLTYVRGSVGPATSTLMFVAGVVGNGLALGILSARRPARPSAFA...	unknown	agonist
Prostaglandin E2 receptor EP2 subtype	MGNASNDSQSEDCETRQWLPPGESPAISSVMFSAGVLGNLIALALLARRW...	unknown	agonist
Prostaglandin D2 receptor	MKSPFYRCQNTTSVEKGNSAVMGGVLFSTGLLGNLLALGLLARSGLGWCS...	unknown	agonist
Peroxisome proliferator-activated receptor delta	MEQPQEEAPEVREEEEKEEVAEAEGAPELNGGPQHALPSSSYTDLSRSSS...	unknown	agonist
P2Y purinoceptor 12	MQAVDNLTSAPGNTSLCTRDYKITQVLFPLLYTVLFFVGLITNGLAMRIF...	unknown	agonist
Cytochrome P450 2C8	MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDI...	unknown	substrate
Cytochrome P450 2C9	MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDI...	unknown	substrate
View More

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682